- Home
- CPB vs ROIV Comparison
CPB vs ROIV Comparison
Compare CPB & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPB
- ROIV
- Stock Information
- Founded
- CPB 1869
- ROIV 2014
- Country
- CPB United States
- ROIV United Kingdom
- Employees
- CPB N/A
- ROIV N/A
- Industry
- CPB Packaged Foods
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- CPB Consumer Staples
- ROIV Health Care
- Exchange
- CPB Nasdaq
- ROIV Nasdaq
- Market Cap
- CPB 9.2B
- ROIV 8.6B
- IPO Year
- CPB N/A
- ROIV N/A
- Fundamental
- Price
- CPB $30.98
- ROIV $17.31
- Analyst Decision
- CPB Hold
- ROIV Strong Buy
- Analyst Count
- CPB 16
- ROIV 8
- Target Price
- CPB $34.20
- ROIV $19.94
- AVG Volume (30 Days)
- CPB 5.3M
- ROIV 7.4M
- Earning Date
- CPB 12-02-2025
- ROIV 11-11-2025
- Dividend Yield
- CPB 5.05%
- ROIV N/A
- EPS Growth
- CPB 6.35
- ROIV N/A
- EPS
- CPB 2.01
- ROIV N/A
- Revenue
- CPB $10,253,000,000.00
- ROIV $23,233,000.00
- Revenue This Year
- CPB N/A
- ROIV N/A
- Revenue Next Year
- CPB $1.16
- ROIV $200.91
- P/E Ratio
- CPB $15.35
- ROIV N/A
- Revenue Growth
- CPB 6.40
- ROIV N/A
- 52 Week Low
- CPB $29.39
- ROIV $8.73
- 52 Week High
- CPB $48.74
- ROIV $17.33
- Technical
- Relative Strength Index (RSI)
- CPB 45.25
- ROIV 82.30
- Support Level
- CPB $29.69
- ROIV $15.91
- Resistance Level
- CPB $30.56
- ROIV $16.39
- Average True Range (ATR)
- CPB 0.67
- ROIV 0.52
- MACD
- CPB -0.04
- ROIV 0.03
- Stochastic Oscillator
- CPB 46.84
- ROIV 97.92
About CPB Campbell Soup Company
Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2024 (July year-end), snacks accounted for nearly half of its revenue, followed by soup (28%), other simple meals (17%), and beverages (7%). Outside its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and recently acquired Rao's (a deal that closed in March 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.